Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity

Oncotarget

Volumn 5, Issue 10, 2014, Pages 3039-3054

  Raimondi, Lavinia ^a   Amodio, Nicola ^a   di Martino, Maria Teresa ^a   Altomare, Emanuela ^a   Leotta, Marzia ^a   Caracciolo, Daniele ^a   Gullà, Annamaria ^a   Neri, Antonino ^b   Taverna, Simona ^c   D'Aquila, Patrizia ^d   Alessandro, Riccardo ^c   Giordano, Antonio ^e   Tagliaferri, Pierosandro ^a   Tassone, Pierfrancesco ^a,e  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d UNIVERSITY OF CALABRIA   (Italy)

^e Temple University   (United States)

Author keywords

Angiogenesis; Hypoxia; Microenviroment; MicroRNA; miR 199 5p; MiRNA; Multiple myeloma; Plasma cell leukemia

Indexed keywords

DISCOIDIN; DISCOIDIN DOMAIN RECEPTOR 1 PROTEIN; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; MICRORNA; MICRORNA 199A 5P; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN A; MIRN199 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL ADHESION; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FIBROBLAST GROWTH FACTOR 2 GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HYPOXIA; IL 8 GENE; MALE; MMP 2 GENE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; TUMOR VASCULARIZATION; VEGF A GENE; ANIMAL; CELL HYPOXIA; CELL MOTION; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC TRANSFECTION; GENETICS; IN VITRO STUDY; NEOVASCULARIZATION (PATHOLOGY); NONOBESE DIABETIC MOUSE; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL ADHESION; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IN VITRO TECHNIQUES; MICE; MICE, INBRED NOD; MICE, SCID; MICRORNAS; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; REAL-TIME POLYMERASE CHAIN REACTION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902085012     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1747     Document Type: Article

References (76)

1. Palumbo A and Anderson K. Multiple myeloma. N Engl J Med. 2011; 364(11):1046-1060.
2. Munshi NC and Anderson KC. New strategies in the treatment of multiple myeloma. Clin Cancer Res. 2013; 19(13):3337-3344.
3. Calimeri T, Battista E, Conforti F, Neri P, Di Martino MT, Rossi M, Foresta U, Piro E, Ferrara F, Amorosi A, Bahlis N, Anderson KC, Munshi N, Tagliaferri P, Causa F and Tassone P. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia. 25(4):707-711.
4. Tassone P, Neri P, Carrasco DR, Burger R, Goldmacher VS, Fram R, Munshi V, Shammas MA, Catley L, Jacob GS, Venuta S, Anderson KC and Munshi NC. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood. 2005; 106(2):713-716.
5. Tassone P, Neri P, Burger R, Di Martino MT, Leone E, Amodio N, Caraglia M and Tagliaferri P. Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Curr Cancer Drug Targets. 2012; 12(7):814-822.
6. Rossi M, Di Martino MT, Morelli E, Leotta M, Rizzo A, Grimaldi A, Misso G, Tassone P and Caraglia M. Molecular targets for the treatment of multiple myeloma. Curr Cancer Drug Targets. 2012; 12(7):757-767.
7. Misso G, Zappavigna S, Castellano M, De Rosa G, Di Martino MT, Tagliaferri P, Tassone P and Caraglia M. Emerging pathways as individualized therapeutic target of multiple myeloma. Expert opinion on biological therapy. 2013; 13 Suppl 1:S95-109.
8. Giuliani N, Storti P, Bolzoni M, Palma BD and Bonomini S. Angiogenesis and multiple myeloma. Cancer Microenviron. 4(3):325-337.
9. Fan F, Schimming A, Jaeger D and Podar K. Targeting the tumor microenvironment: focus on angiogenesis. J Oncol. 2012:281261.
10. Samant RS and Shevde LA. Recent advances in anti-angiogenic therapy of cancer. Oncotarget. 2011; 2(3):122-134.
11. Jakob C, Sterz J, Zavrski I, Heider U, Kleeberg L, Fleissner C, Kaiser M and Sezer O. Angiogenesis in multiple myeloma. Eur J Cancer. 2006; 42(11):1581-1590.
12. Ribatti D, Mangialardi G and Vacca A. Antiangiogenic therapeutic approaches in multiple myeloma. Curr Cancer Drug Targets. 2012; 12(7):768-775.
13. Hickey MM and Simon MC. Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Curr Top Dev Biol. 2006; 76:217-257.
14. Martin SK, Diamond P, Williams SA, To LB, Peet DJ, Fujii N, Gronthos S, Harris AL and Zannettino AC. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica. 95(5):776-784.
15. Martin SK, Diamond P, Gronthos S, Peet DJ and Zannettino AC. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia. 25(10):1533-1542.
16. Zhang Y, Li M, Yao Q and Chen C. Recent advances in tumor hypoxia: tumor progression, molecular mechanisms, and therapeutic implications. Med Sci Monit. 2007; 13(10):RA175-180.
17. Storti P, Bolzoni M, Donofrio G, Airoldi I, Guasco D, Toscani D, Martella E, Lazzaretti M, Mancini C, Agnelli L, Patrene K, Maiga S, Franceschi V, Colla S, Anderson J, Neri A, et al. Hypoxia-inducible factor (HIF)-1alpha suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia. 27(8):1697-1706.
18. Hua Z, Lv Q, Ye W, Wong CK, Cai G, Gu D, Ji Y, Zhao C, Wang J, Yang BB and Zhang Y. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One. 2006; 1:e116.
19. Landskroner-Eiger S, Moneke I and Sessa WC. miRNAs as modulators of angiogenesis. Cold Spring Harb Perspect Med. 3(2):a006643.
20. Calin GA and Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857-866.
21. Lionetti M, Agnelli L, Mosca L, Fabris S, Andronache A, Todoerti K, Ronchetti D, Deliliers GL and Neri A. Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosomes Cancer. 2009; 48(6):521-531.
22. Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S, Sales G, Deliliers GL, Bicciato S, Lombardi L, Bortoluzzi S and Neri A. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood. 2009; 114(25):e20-26.
23. Lionetti M, Agnelli L, Lombardi L, Tassone P and Neri A. MicroRNAs in the pathobiology of multiple myeloma. Curr Cancer Drug Targets. 2012; 12(7):823-837.
24. Benetatos L and Vartholomatos G. Deregulated microRNAs in multiple myeloma. Cancer. 2012; 118(4):878-887.
25. Chou J, Shahi P and Werb Z. microRNA-mediated regulation of the tumor microenvironment. Cell Cycle. 2013; 12(20):3262-3271.
26. Nohata N, Hanazawa T, Enokida H and Seki N. microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers. Oncotarget. 2012; 3(1):9-21.
27. Calin GA and Croce CM. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene. 2006; 25(46):6202-6210.
28. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, Munker R, Volinia S, Boccadoro M, Garzon R, Palumbo A, Aqeilan RI, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A. 2008; 105(35):12885-12890.
29. Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, Gulla A, Neri A and Tassone P. Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets. 2012; 12(7):838-846.
30. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Cantafio ME, Gulla A, Conforti F, Morelli E, Tomaino V, Rossi M, Negrini M, Ferrarini M, Caraglia M, Shammas MA, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res. 2012; 18(22):6260-6270.
31. Amodio N, Leotta M, Bellizzi D, Di Martino MT, D'Aquila P, Lionetti M, Fabiani F, Leone E, Gulla AM, Passarino G, Caraglia M, Negrini M, Neri A, Giordano A, Tagliaferri P and Tassone P. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget. 2012; 3(10):1246-1258.
32. Amodio N, Di Martino MT, Foresta U, Leone E, Lionetti M, Leotta M, Gulla AM, Pitari MR, Conforti F, Rossi M, Agosti V, Fulciniti M, Misso G, Morabito F, Ferrarini M, Neri A, et al. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis. 2012; 3:e436.
33. Rossi M, Pitari MR, Amodio N, Di Martino MT, Conforti F, Leone E, Botta C, Paolino FM, Del Giudice T, Iuliano E, Caraglia M, Ferrarini M, Giordano A, Tagliaferri P and Tassone P. miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol. 2013; 228(7):1506-1515.
34. Di Martino MT, Gulla A, Cantafio ME, Lionetti M, Leone E, Amodio N, Guzzi PH, Foresta U, Conforti F, Cannataro M, Neri A, Giordano A, Tagliaferri P and Tassone P. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget. 2013; 4(2):242-255.
35. Amodio N, Di Martino MT, Neri A, Tagliaferri P and Tassone P. Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. Expert Opin Biol Ther. 2013; 13 Suppl 1:S125-137.
36. Amodio N, Bellizzi D, Leotta M, Raimondi L, Biamonte L, D'Aquila P, Di Martino MT, Calimeri T, Rossi M, Lionetti M, Leone E, Passarino G, Neri A, Giordano A, Tagliaferri P and Tassone P. miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle. 2013; 12(23): 3650-3662.
37. Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gulla A, Rossi M, Neri A, Giordano A, Munshi NC, Anderson KC, Tagliaferri P and Tassone P. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19(8):2096-2106.
38. Kulshreshtha R, Davuluri RV, Calin GA and Ivan M. A microRNA component of the hypoxic response. Cell Death Differ. 2008; 15(4):667-671.
39. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, Calin GA and Ivan M. A microRNA signature of hypoxia. Mol Cell Biol. 2007; 27(5):1859-1867.
40. Chan SY and Loscalzo J. MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle. 2010; 9(6):1072-1083.
41. Shen Q, Cicinnati VR, Zhang X, Iacob S, Weber F, Sotiropoulos GC, Radtke A, Lu M, Paul A, Gerken G and Beckebaum S. Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol Cancer. 9:227.
42. Gu S and Chan WY. Flexible and Versatile as a Chameleon-Sophisticated Functions of microRNA-199a. Int J Mol Sci. 13(7):8449-8466.
43. Song XW, Li Q, Lin L, Wang XC, Li DF, Wang GK, Ren AJ, Wang YR, Qin YW, Yuan WJ and Jing Q. MicroRNAs are dynamically regulated in hypertrophic hearts, and miR-199a is essential for the maintenance of cell size in cardiomyocytes. J Cell Physiol. 225(2):437-443.
44. Sayed D and Abdellatif M. AKT-ing via microRNA. Cell Cycle. 2010; 9(16):3213-3217.
45. Rane S, He M, Sayed D, Yan L, Vatner D and Abdellatif M. An antagonism between the AKT and beta-adrenergic signaling pathways mediated through their reciprocal effects on miR-199a-5p. Cell Signal. 22(7):1054-1062.
46. Cheung HH, Davis AJ, Lee TL, Pang AL, Nagrani S, Rennert OM and Chan WY. Methylation of an intronic region regulates miR-199a in testicular tumor malignancy. Oncogene. 30(31):3404-3415.
47. Lujambio A and Esteller M. How epigenetics can explain human metastasis: a new role for microRNAs. Cell Cycle. 2009; 8(3):377-382.
48. Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P, Sortino G and Giustolisi R. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica. 2000; 85(8):800-805.
49. Podar K and Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood. 2005; 105(4):1383-1395.
50. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2(1):38-47.
51. Guimbellot JS, Erickson SW, Mehta T, Wen H, Page GP, Sorscher EJ and Hong JS. Correlation of microRNA levels during hypoxia with predicted target mRNAs through genome-wide microarray analysis. BMC Med Genomics. 2009; 2:15.
52. Ghosh G, Subramanian IV, Adhikari N, Zhang X, Joshi HP, Basi D, Chandrashekhar YS, Hall JL, Roy S, Zeng Y and Ramakrishnan S. Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-alpha isoforms and promotes angiogenesis. J Clin Invest. 120(11):4141-4154.
53. Cascio S, D'Andrea A, Ferla R, Surmacz E, Gulotta E, Amodeo V, Bazan V, Gebbia N and Russo A. miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J Cell Physiol. 224(1):242-249.
54. Jia XQ, Cheng HQ, Qian X, Bian CX, Shi ZM, Zhang JP, Jiang BH and Feng ZQ. Lentivirus-mediated overexpression of microRNA-199a inhibits cell proliferation of human hepatocellular carcinoma. Cell Biochem Biophys. 62(1):237-244.
55. Rane S, He M, Sayed D, Vashistha H, Malhotra A, Sadoshima J, Vatner DE, Vatner SF and Abdellatif M. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res. 2009; 104(7):879-886.
56. Gutierrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV, Ferminan E, Martin-Jimenez P, Chillon C, Risueno A, Hernandez JM, Garcia-Sanz R, Gonzalez M and San Miguel JF. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia. 24(3):629-637.
57. Kriegl L, Vieth M, Kirchner T and Menssen A. Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer. Oncotarget. 2012; 3(10):1182-1193.
58. Colla S, Morandi F, Lazzaretti M, Polistena P, Svaldi M, Coser P, Bonomini S, Hojden M, Martella E, Chisesi T, Rizzoli V and Giuliani N. Do human myeloma cells directly produce basic FGF? Blood. 2003; 102(8):3071-3072; author reply 3072-3073.
59. Colla S, Tagliaferri S, Morandi F, Lunghi P, Donofrio G, Martorana D, Mancini C, Lazzaretti M, Mazzera L, Ravanetti L, Bonomini S, Ferrari L, Miranda C, Ladetto M, Neri TM, Neri A, et al. The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. Blood. 2007; 110(13):4464-4475.
60. Ria R, Reale A, De Luisi A, Ferrucci A, Moschetta M and Vacca A. Bone marrow angiogenesis and progression in multiple myeloma. Am J Blood Res. 1(1):76-89.
61. Vacca A and Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia. 2006; 20(2):193-199.
62. Liu YL, Yu JM, Song XR, Wang XW, Xing LG and Gao BB. Regulation of the chemokine receptor CXCR4 and metastasis by hypoxia-inducible factor in non small cell lung cancer cell lines. Cancer Biol Ther. 2006; 5(10):1320-1326.
63. Sarvaiya PJ, Guo D, Ulasov I, Gabikian P and Lesniak MS. Chemokines in tumor progression and metastasis. Oncotarget. 2013; 4(12): 2171-2185.
64. Vogel WF, Aszodi A, Alves F and Pawson T. Discoidin domain receptor 1 tyrosine kinase has an essential role in mammary gland development. Mol Cell Biol. 2001; 21(8):2906-2917.
65. Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, Thompson B, Maiso P, Sun JD, Hart CP, Roccaro AM, Sacco A, Ngo HT, Lin CP, Kung AL, Carrasco RD, et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood. 119(24):5782-5794.
66. Guarino M, Rubino B and Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007; 39(3):305-318.
67. Christiansen JJ and Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinomainvasion and metastasis. Cancer Res. 2006; 66(17):8319-8326.
68. Zhu GH, Huang C, Feng ZZ, Lv XH and Qiu ZJ. Hypoxia-induced snail expression through transcriptional regulation by HIF-1alpha in pancreatic cancer cells. Dig Dis Sci. 58(12):3503-3515.
69. Radisavljevic Z. AKT as locus of cancer multidrug resistance and fragility. J Cell Physiol. 228(4):671-674.
70. Markman B, Dienstmann R and Tabernero J. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget. 2010; 1(7):530-543.
71. Lee YB, Bantounas I, Lee DY, Phylactou L, Caldwell MA and Uney JB. Twist-1 regulates the miR-199a/214 cluster during development. Nucleic Acids Res. 2009; 37(1):123-128.
72. Misiewicz-Krzeminska I, Sarasquete ME, Quwaider D, Krzeminski P, Ticona FV, Paino T, Delgado M, Aires A, Ocio EM, Garcia-Sanz R, San Miguel JF and Gutierrez NC. Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication. Haematologica. 98(4):640-648.
73. Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y and Sasaki H. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 2001; 97(5):1172-1179.
74. Castiglia D, Cestelli A, Scaturro M, Nastasi T and Di Liegro I. H1(0) and H3.3B mRNA levels in developing rat brain. Neurochem Res. 1994; 19(12):1531-1537.
75. Cestelli A, Castiglia D, Di Liegro C and Di Liegro I. Qualitative differences in nuclear proteins correlate with neuronal terminal differentiation. Cell Mol Neurobiol. 1992; 12(1):33-43.
76. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Cantafio ME, Gulla A, Conforti F, Morelli E, Tomaino V, Rossi M, Negrini M, Ferrarini M, Caraglia M, Shammas MA, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res. 18(22):6260-6270.